[go: up one dir, main page]

KR950704257A - 매트릭스 메탈로프로테이나제 억제제로서의 카보스티릴 유도체(Carbostyril derivatives as matrix metalloproteinases inhibitors) - Google Patents

매트릭스 메탈로프로테이나제 억제제로서의 카보스티릴 유도체(Carbostyril derivatives as matrix metalloproteinases inhibitors)

Info

Publication number
KR950704257A
KR950704257A KR1019940704126A KR19940704126A KR950704257A KR 950704257 A KR950704257 A KR 950704257A KR 1019940704126 A KR1019940704126 A KR 1019940704126A KR 19940704126 A KR19940704126 A KR 19940704126A KR 950704257 A KR950704257 A KR 950704257A
Authority
KR
South Korea
Prior art keywords
matrix metalloproteinases
carbostyril derivatives
metalloproteinases inhibitors
inhibitors
carbostyril
Prior art date
Application number
KR1019940704126A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950704257A publication Critical patent/KR950704257A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1019940704126A 1993-03-18 1994-11-18 매트릭스 메탈로프로테이나제 억제제로서의 카보스티릴 유도체(Carbostyril derivatives as matrix metalloproteinases inhibitors) KR950704257A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5826493 1993-03-18
JP25687393 1993-10-14
PCT/JP1994/000434 WO1994021612A1 (en) 1993-03-18 1994-03-17 Carbostyril derivatives as matrix metalloproteinases inhibitors

Publications (1)

Publication Number Publication Date
KR950704257A true KR950704257A (ko) 1995-11-17

Family

ID=26399315

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704126A KR950704257A (ko) 1993-03-18 1994-11-18 매트릭스 메탈로프로테이나제 억제제로서의 카보스티릴 유도체(Carbostyril derivatives as matrix metalloproteinases inhibitors)

Country Status (7)

Country Link
EP (1) EP0641323A1 (ko)
KR (1) KR950704257A (ko)
CN (1) CN1105799A (ko)
AU (1) AU672888B2 (ko)
CA (1) CA2136108A1 (ko)
TW (1) TW290541B (ko)
WO (1) WO1994021612A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
ATE205184T1 (de) 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren
WO1997024117A1 (en) * 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
DE69710182T2 (de) * 1996-04-04 2002-08-29 F. Hoffmann-La Roche Ag, Basel Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
CZ298048B6 (cs) 1996-09-10 2007-06-06 British Biotech Pharmaceuticals Limited Farmaceutický prostredek a deriváty kyseliny hydroxamové
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE60219630T2 (de) 2001-06-15 2007-12-27 Vicuron Pharmaceuticals, Inc., Fremont Bicyclische pyrrolidinverbindungen
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2005011811A1 (en) 2003-07-30 2005-02-10 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for accelerating salivation
CN108285469B (zh) * 2018-03-15 2020-07-24 遵义医学院 一种抗菌类喹诺酮衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
WO1994021612A1 (en) 1994-09-29
AU672888B2 (en) 1996-10-17
CN1105799A (zh) 1995-07-26
CA2136108A1 (en) 1994-09-29
EP0641323A1 (en) 1995-03-08
AU6263794A (en) 1994-10-11
TW290541B (ko) 1996-11-11

Similar Documents

Publication Publication Date Title
KR950704257A (ko) 매트릭스 메탈로프로테이나제 억제제로서의 카보스티릴 유도체(Carbostyril derivatives as matrix metalloproteinases inhibitors)
NO942064D0 (no) yminhibitorer
FI944804A0 (fi) Pyrimidinyyliasetamideja elastaasin estäjinä
FI972160L (fi) Matriisimetalloproteaasi-inhibiittorit
ATE222240T1 (de) Hiv - protease inhibitoren
FI962315A0 (fi) Entsyymi-inhibiittorit
FI20012510L (fi) Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
NO932620D0 (no) Amindiol-proteaseinhibitorer
FI954404L (fi) Fenoksifenyylietikkahappojohdannaiset
FI962022L (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
FI940573L (fi) Geneseriinin johdannaiset koliiniestraasin inhibiittoreina
DE69429147D1 (de) Benzamidderivate
FI945674L (fi) Substituoidut 2beta-morfoliini-androstaanijohdannaiset
FI961044L (fi) Kininogeeni-inhibiittorit
KR950702832A (ko) 아미노산 유도체(amino acid derivative)
KR960703888A (ko) 이소플라본 유도체 (isoflavone derivatives)
EE9900180A (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
FI962021L (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
FI101796B1 (fi) Uusia -glukosidaasi-inhibiittoreita
DE59402621D1 (de) Fluor-trifluormethylbenzoesäure-Derivate
ATE205822T1 (de) Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren
FI960730L (fi) Indolijohdannaiset 5alfa-reduktaasi-1-inhibiittoreina
NO962015D0 (no) Pyron-derivater som protease-inhibitorer og antivirus-midler
FI941259L (fi) Uudet alfa-mannosidaasiestäjät
FI962020L (fi) Pyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19941118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid